Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Obstetrics and Gynecology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- UNAIDS. Start Free, Stay Free, AIDS Free: Final report on 2020 targets.(Available at:)
- Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States.(Available at:) (Accessed October 09 2022)
- Epidemiology of Perinatal HIV Transmission in the United States in the Era of Its Elimination.Pediatr Infect Dis J. 2019; 38: 611-616
- Enhanced and Timely Investigation of ARVs for Use in Pregnant Women.J Acquir Immune Defic Syndr. 2021; 86: 607-615
- Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.Plos Med. 2016; 13: e1002160
- Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus.Clin Infect Dis. 2019; 69: 1254-1258
- Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint.AIDS. 2019; 33: 1089-1093
- Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women.Expert Opin Drug Metab Toxicol. 2019; 15: 523-525
- Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.J Acquir Immune Defic Syndr. 2010; 54: 381-388
- Atazanavir pharmacokinetics with and without tenofovir during pregnancy.J Acquir Immune Defic Syndr. 2011; 56: 412-419
- Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.J Acquir Immune Defic Syndr. 2015; 70: 33-41
- Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.AIDS. 2018; 32: 2507-2516
- Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.J Acquir Immune Defic Syndr. 2022; 89: 303-309
- Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.AIDS. 2021; 35: 1191-1199
- Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.HIV Med. 2019; 20: 337-343
- Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.AIDS. 2021; 35: 407-417
- Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.J Acquir Immune Defic Syndr. 2022; 90: 343-350
- Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.HIV Med. 2011; 12: 570-579
- Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.J Acquir Immune Defic Syndr. 2013; 63: 59-66
- Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.J Antimicrob Chemother. 2015; 70: 534-542
- Darunavir Pharmacokinetics With an Increased Dose During Pregnancy.J Acquir Immune Defic Syndr. 2020; 83: 373-380
- Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.Antimicrob Agents Chemother. 2014; 58: 2884-2893
- Lopinavir protein binding in HIV-1-infected pregnant women.HIV Med. 2010; 11: 232-238
- Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.CPT Pharmacometrics Syst Pharmacol. 2016; 5: 147-157
- Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.J Antimicrob Chemother. 2015; 70: 217-224
- Impact of pregnancy on abacavir pharmacokinetics.AIDS. 2006; 20: 553-560
- The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women.AIDS. 2016; 30: 1239-1244
- Effect of pregnancy on emtricitabine pharmacokinetics.HIV Med. 2012; 13: 226-235
- Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women.Antimicrob Agents Chemother. 2012; 56: 776-782
- Pharmacokinetics of tenofovir during pregnancy and postpartum.HIV Med. 2015; 16: 502-511
- Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.Clin Infect Dis. 2022; 75: 623-629
- Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.J Infect Dis. 1998; 178: 1327-1333
- Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.Clin Infect Dis. 2021; 73: e1893-e1900
- Efavirenz pharmacokinetics during pregnancy and infant washout.Antivir Ther. 2019; 24: 95-103
- Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV.Clin Ther. 2020; 42: 1818-1825
- Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6?.Eur J Clin Pharmacol. 2020; 76: 1143-1150
- Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.Infect Dis Ther. 2018; 7: 147-159
- Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.J Acquir Immune Defic Syndr. 2016; 72: 289-296
- Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.HIV Med. 2008; 9: 214-220
- Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.J Acquir Immune Defic Syndr. 2010; 55: 345-350
- Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.Front Pharmacol. 2016; 7: 239
- Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments.Clin Pharmacokinet. 2022; 61: 1129-1141
- The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.Clin Infect Dis. 2021; 72: 121-127
- Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.AIDS. 2018; 32: 729-737
- Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).Plos Med. 2019; 16: e1002895
- Raltegravir pharmacokinetics during pregnancy.J Acquir Immune Defic Syndr. 2014; 67: 375-381
- Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.Clin Infect Dis. 2020; 71: e714-e717
- First pharmacokinetic data of bictegravir in pregnant women living with HIV.AIDS. 2021; 35: 2405-2406
- Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.Clin Infect Dis. 2015; 61: 1582-1589
Organization WH. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. Accessed 08 Oct, 2022. Updated 26 January 2021 Available at:. https://www.who.int/news/item/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
